Literature DB >> 16380829

A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents.

S V Koroleva1, I P Ashmarin.   

Abstract

Regulatory peptides are actively involved in controlling most physiological processes. One such function is regulation of the level of anxiety and panic states. We report here a meta-analysis of data published from 1960 to 2004 on the effects of anxiety-enhancing regulatory peptides. The resulting database was used to investigate the organization and functioning of the anxiogenic regulatory peptide system. Using vector representation of the effects of these peptides, the spectra of physiological effects which might be provoked by each anxiety- and fear-increasing regulatory peptide alone and in combination were evaluated. Complexes of regulatory peptides with anxiogenic profiles with the greatest potential for the further experimental development of inhibitory pharmacological agents were identified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16380829     DOI: 10.1007/s11055-005-0174-2

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  46 in total

1.  CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects.

Authors:  I Jerabek; J P Boulenger; J Bradwejn; Y J Lavallée; F B Jolicoeur
Journal:  Eur Neuropsychopharmacol       Date:  1999-01       Impact factor: 4.600

2.  [Functional classification of regulator peptides. Divergent and convergent evolution of regulator peptides].

Authors:  S V Koroleva; I P Ashmarin
Journal:  Zh Evol Biokhim Fiziol       Date:  2000 Mar-Apr

3.  Selective activation of CCK-B receptors does not induce sleep and does not affect EEG slow-wave activity and brain temperature in rats.

Authors:  H Y Chang; L Kapás
Journal:  Physiol Behav       Date:  1997-07

4.  Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze.

Authors:  K T Britton; Y Akwa; M G Spina; G F Koob
Journal:  Peptides       Date:  2000-01       Impact factor: 3.750

5.  V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.

Authors:  R Landgraf; R Gerstberger; A Montkowski; J C Probst; C T Wotjak; F Holsboer; M Engelmann
Journal:  J Neurosci       Date:  1995-06       Impact factor: 6.167

6.  Effect of cholecystokinin octapeptide analogues on food intake in the dog.

Authors:  A Inui; M Okita; T Inoue; N Sakatani; M Oya; H Morioka; M Oimomi; S Baba
Journal:  Am J Physiol       Date:  1989-10

7.  Vasopressin alters female sexual behaviour by acting on the brain independently of alterations in blood pressure.

Authors:  P Södersten; M Henning; P Melin; S Ludin
Journal:  Nature       Date:  1983 Feb 17-23       Impact factor: 49.962

8.  The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice.

Authors:  F Hernando; J A Fuentes; B P Roques; M Ruiz-Gayo
Journal:  Eur J Pharmacol       Date:  1994-08-22       Impact factor: 4.432

9.  Inhibitory influence of corticotropin releasing factor on components of sexual behaviour in the male rat.

Authors:  D J Sirinathsinghji
Journal:  Brain Res       Date:  1987-03-24       Impact factor: 3.252

10.  Effects of central administration of arginine-vasopressin on aversive memory retrieval.

Authors:  K B Kumar; K S Karanth
Journal:  Brain Res       Date:  1995-11-20       Impact factor: 3.252

View more
  1 in total

1.  Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.

Authors:  P A Slominsky; M I Shadrina; T A Kolomin; A V Stavrovskaya; E V Filatova; L A Andreeva; S N Illarioshkin; N F Myasoedov
Journal:  Dokl Biol Sci       Date:  2017-07-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.